Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Longitudinal immune monitoring in patients treated with CD19 and BCMA CAR-T cells using standardized 8‑color flow cytometry panel reveals substantial differences among products kinetics and persistence

View Full Paper
Ask AI
Bookmark
Share

Authors

OSOndřej SoučekLVLenka Janska VojtkovaMBMarek Borský

Discussion

Loading...

Member takes

Overview

Multicenter analysis demonstrates differing kinetics and persistence of CAR-T cell therapies in patients, indicating clinical efficacy and toxicity patterns.

Key Points

  • To compare longitudinal kinetics of CAR-T and non-CAR-T immune subsets among various CD19 and BCMA CAR-T products.
  • Analyzed 727 peripheral blood samples from 123 patients treated with CAR-T products
  • Standardized 8-color flow cytometry panel was utilized
  • Samples collected at baseline and monthly to Month 15
  • Different CAR-T products showed substantial differences in expansion and persistence
  • Cilta-cel had higher peak counts but disappeared by month three, while axi-cel showed prolonged presence
  • Higher CAR-T counts correlated with increased toxicity and improved survival outcomes

Cite This Study

Souček et al. (2025) studied this question.

synapsesocial.com/papers/69362f484fa91c937236d6d3https://doi.org/10.1182/blood-2025-5721
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1BCMA CAR T-cell expansion dynamics and toxicity after idecabtagene vicleucel and ciltacabtagene autoleucel for multiple myeloma2025
  2. 2Prognostic impact of CAR-T cell expansion and PD1 expression in patients with DLBCL treated with axicabtagene ciloleucel2025
  3. 3Assessment of long-term persistence and phenotypic features of BCMA CAR-T cells in patients with relapsed or refractory multiple myeloma treated with ciltacabtagene autoleucel.2026
  4. 4Lymphocyte kinetics as a predictor of clinical outcomes following CAR-T therapy for non-Hodgkin lymphoma2025
  5. 5Single-cell transcriptomics reveal mechanisms of efficacy and toxicity in anti-BCMA CAR-T cell therapies for multiple myeloma2025